10-Q: BiomX Q3 2025: Losses Mount, Clinical Hold on CF Trial

BiomX reported a significant increase in net loss for Q3 2025, alongside a going concern warning, while its lead cystic fibrosis program faced an FDA clinical hold.

Summary

• BiomX reported a net loss of $9.2 million for the three months ended September 30, 2025, a substantial increase from a net income of $9.6 million in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss was $22.9 million, up from $3.2 million in the prior year period.
• Research and development (R&D) expenses, net, decreased by 16% to $6.1 million for the three months ended September 30, 2025, and by 10% to $16.4 million for the nine months ended September 30, 2025, primarily due to workforce reduction and reduced rent expenses.
• General and administrative expenses decreased by 25% to $2.4 million for the three months and by 17% to $7.3 million for the nine months ended September 30, 2025.
• Cash and cash equivalents significantly decreased to $6.9 million as of September 30, 2025, from $16.9 million at December 31, 2024.
• The company's accumulated deficit reached $203.6 million as of September 30, 2025.
• Management believes current funds are sufficient only into the first quarter of 2026, raising substantial doubt about the company's ability to continue as a going concern.
• The FDA placed a clinical hold on the U.S. portion of the Phase 2b study for BX004 (Cystic Fibrosis) in August 2025, related to a third-party nebulizer device, though the EU study continues.
• Topline results for the BX004 Phase 2b study are still expected in the first quarter of 2026.
• Positive Phase 2 results for BX211 (Diabetic Foot Osteomyelitis) were announced in March 2025, showing statistically significant improvements in ulcer size and depth.
• BiomX is prioritizing BX011 (Diabetic Foot Infections) for a Phase 2a trial, subject to financial resources, before expanding to DFO patient populations.
• The company completed several capital raises, including a February 2025 financing for $5.5 million gross proceeds and warrant exercises generating $6.5 million, and additional ATM sales of $1.3 million through November 11, 2025.
• Stockholders authorized a reverse stock split (1-for-5 to 1-for-20) on October 16, 2025, to be determined by the Board before October 16, 2026.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to a significant increase in net losses, a critical 'going concern' warning, and an FDA clinical hold on a lead program. While there are positive clinical trial results for another program and cost reductions, the financial instability and regulatory setback outweigh these.

Positives

• Net cash used in operating activities decreased to $22.0 million for the nine months ended September 30, 2025, from $30.7 million in the prior year, indicating improved cash burn efficiency.
• R&D expenses and General and administrative expenses both decreased for the three and nine months ended September 30, 2025, reflecting cost-cutting measures including workforce reduction.
• Positive Phase 2 results for BX211 in Diabetic Foot Osteomyelitis (DFO) were announced in March 2025, demonstrating statistically significant improvements in ulcer size reduction (p = 0.046 at week 12) and ulcer depth (p=0.048 at week 13).
• The European portion of the BX004 Phase 2b study for Cystic Fibrosis continues enrollment and dosing, with topline results still expected in Q1 2026.
• The FDA recognized a significant unmet need for therapies addressing chronic Pseudomonas aeruginosa infection in individuals with CF, outlining potential development pathways for a Phase 3 program.
• BiomX believes it has fully addressed the FDA's queries regarding the third-party nebulizer for BX004, with no concerns raised about the drug product itself.

Negatives

• The company reported a net loss of $9.2 million for the three months ended September 30, 2025, a significant reversal from a net income of $9.6 million in the same period of 2024.
• The net loss for the nine months ended September 30, 2025, increased substantially to $22.9 million from $3.2 million in the prior year period.
• Cash and cash equivalents decreased significantly to $6.9 million as of September 30, 2025, from $16.9 million at December 31, 2024.
• The accumulated deficit grew to $203.6 million as of September 30, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern, as current funds are projected to last only into the first quarter of 2026.
• The FDA placed a clinical hold on the U.S. portion of the Phase 2b study for BX004, pausing patient screening and enrollment in the U.S.
• The company continues to rely on future issuances of equity or debt, loans, and grants to fund operations, which are subject to market conditions and may result in further dilution.

Risks

• Inability to generate revenues and raise sufficient financing to meet working capital requirements and continue as a going concern.
• Effects of a prolonged shutdown of the U.S. federal government on operations, including the FDA or SEC.
• Unpredictable timing and cost associated with developing product candidates using phage technology and potential success thereof.
• Political, economic, and military instability in the State of Israel, including the war in Iran, Gaza, and Lebanon, and potential conflicts with other Middle Eastern countries.
• Obtaining FDA acceptance of non-U.S. clinical trials, including the lifting of the clinical hold imposed on the Phase 2b clinical trial for BX004.
• Ability to enroll patients in clinical trials and achieve anticipated development milestones when expected.
• Penalties and market withdrawal associated with unanticipated problems with product candidates and failure to comply with labeling and other restrictions.
• General economic conditions, current low stock price, and other factors affecting operations and ability to raise additional capital.
• Delays in developing manufacturing processes for product candidates.
• Competition from similar technologies, more effective, safer, or more affordable products, or products that obtain marketing approval sooner.
• Impact of unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• Infringement on the intellectual property rights of third parties and claims for remuneration or royalties for assigned service invention rights.
• Ethical, legal, and social concerns about synthetic biology and genetic engineering that may adversely affect market acceptance.
• Reliance on third-party collaborators.
• Potential security breaches, including cybersecurity incidents.

Future Outlook

Management estimates that current liquidity resources will be sufficient to fund operations only into the first quarter of 2026. The company expects to continue incurring additional losses in the foreseeable future and does not anticipate generating significant revenues from product sales in the next twelve months. Future funding will be sought through public or private equity, debt financing, loans, and grants, with the ability to raise capital dependent on market conditions and the U.S. federal government shutdown.

Management Comments

• Management believes current funds are sufficient to fund operations into the first quarter of 2026.
• Management believes there is substantial doubt about the company's ability to continue as a going concern.
• Management believes it has fully addressed the FDA's queries relating to the third-party nebulizer for BX004.
• The ongoing war with Hamas, Hezbollah, and Iran has not, since its inception, materially impacted BiomX's business or operations, and no delays to programs are expected as a result of the situation.

Industry Context

BiomX operates in the emerging field of phage therapy, developing treatments for chronic bacterial infections where antibiotic resistance is a significant challenge. Its focus on cystic fibrosis (CF) and diabetic foot infections (DFI) addresses areas with high unmet medical needs, particularly given the increasing prevalence of multidrug-resistant strains. The FDA's recognition of the unmet need in CF, even with CFTR modulators, underscores the potential for novel approaches like phage therapy. The company's BOLT platform aims to differentiate its fixed and personalized phage cocktails in a competitive biotech landscape.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or results within the industry. It focuses on the company's internal clinical trial results and financial performance.

Corporate Governance

Legal Proceedings

• APT and Oyster signed a settlement agreement on December 18, 2024, which included a payment of $300,000 from APT to Oyster, paid on January 13, 2025, resolving allegations of breach of a collaboration agreement.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing capital raises and potential future equity issuances, as well as uncertainty regarding the company's ability to continue as a going concern.
• Employees may be impacted by workforce reductions, as noted in decreased salaries expenses, and potential instability due to the company's financial condition and geopolitical risks in Israel.
• Patients with Cystic Fibrosis and Diabetic Foot Infections could benefit from the advancement of BX004 and BX011, but the FDA clinical hold on BX004's U.S. trial introduces delays for U.S. patients.
• Creditors and suppliers face increased risk due to the company's 'going concern' warning and reliance on future financing.

Next Steps

• Topline readout of the BX004 Phase 2b study results is expected in the first quarter of 2026.
• Initiate a Phase 2a clinical trial for BX011 in Diabetic Foot Infections (DFI), subject to the availability of necessary financial resources.
• Potentially initiate studies into Non-CF Bronchiectasis (NCFB) as an additional indication for BX004, pending positive data from the CF Phase 2b study.
• RondinX Ltd. is expected to be dissolved on or about December 2, 2025, following voluntary liquidation.
• The Board of Directors may effect a reverse stock split at any ratio between 1-for-5 and less than 1-for-20 at any time before October 16, 2026.

Key Dates

Recommendation

While BiomX has reported positive Phase 2 clinical data for BX211 and continues to advance its BX004 program in Europe, the significant increase in net losses, the explicit 'going concern' warning, and the FDA clinical hold on the U.S. portion of the BX004 trial present substantial risks. The company's reliance on continuous dilutive capital raises to fund operations, coupled with a low stock price and potential for a reverse stock split, indicates a highly speculative investment. A seasoned investor would likely 'hold' existing positions with extreme caution, awaiting clarity on the FDA hold, further clinical milestones, and a more sustainable financial trajectory, while strongly advising against new investments given the high risk of capital impairment.

Keywords

BiomX, PHGE, Phage Therapy, Cystic Fibrosis, Diabetic Foot Infections, DFI, Diabetic Foot Osteomyelitis, DFO, BX004, BX011, BX211, Clinical Trials, Biotechnology, SEC Filing, 10-Q, Going Concern, FDA Clinical Hold, Drug Development